Updated on 3 December 2014
Ranbaxy has the rights to commercialize Infimab in other markets in Southeast Asia and North Africa
Singapore: Epirus Biopharmaceuticals in cooperation with Ranbaxy has launched their first biosimilar product, Infimab, a Remcade biosimilar in India. The Boston-based biopharmaceutical company said that infimab will be manufactured by Reliance Lifesciences at a facility in Mumbai.
Mr Amit Munshi, president and CEO of EPIRUS, said, "The launch of Infimab in the fourth quarter of this year is earlier than anticipated and this demonstrated our ability to execute with our partner."
Infimab represents an affordable solution for patients and may expand patient access to this important medicine. "With this first launch, and a diverse pipeline in development, we look forward to continuing to provide solutions for patients globally," he added.
Epirus has entered into a strategic partnership with Ranbaxy, under the terms of which Ranbaxy has the rights to commercialize Infimab in other markets in Southeast Asia and North Africa.
The product was launched at the Indian Rheumatology Association Conference (IRACON) in Chandigarh, in the presence of over a thousand rheumatologists and doctors from around the country.